Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial

Proprotein convertase subtilisin –kexin type 9 (PCSK9) inhibitors promote substantial and sustained low-density lipoprotein cholesterol lowering and reduce cardiovascular events in high-risk patients treated with statins.1,2 The ODYSSEY OUTCOMES trial (NCT01663402) compared treatment with the PCSK9 inhibitor, alirocumab, with pla cebo in 18,924 patients with recent acute coronary syndromes and residual dyslipidemia despite high-intensity or maximum-tolerated statin therapy.1

Source: The American Journal of Medicine - March 13, 2022 Category: General Medicine Authors: Renato D. Lopes, Patr ícia O. Guimarães, Gregory G. Schwartz, Deepak L. Bhatt, Vera A. Bittner, Andrzej Budaj, Anthony J. Dalby, Rafael Diaz, Shaun G. Goodman, Robert A. Harrington, J. Wouter Jukema, Robert Gabor Kiss, Megan Loy, Robert Pordy, Yann Poul Tags: Brief Observation Source Type: research